Diacerein
A potential therapeutic drug for the management of experimental periodontitis in rats
Keywords:
diacerein, experimental, periodontitis, ratsAbstract
Introduction: Knowledge about the pathogenic process in the progression of periodontal disease indicates that the central cause of periodontal disease is the loss of a healthy balance between microbial virulence factors and the host’s inflammatory response. The aim of this study was to evaluate the potential effectiveness of diacerein as an anti-inflammatory drug in the management of experimental periodontitis in rats.
Methods: The study included 60 albino rats that were divided into two groups. Periodontitis was induced in both groups. The drug group received systemic administration of diacerein, and the control group received a placebo. IL-1ß was measured two weeks after the induction of periodontitis and before the administration of the drug (baseline measurement), and it was measured again at the end of two and end of four weeks after scaling and root planning and diacerein administration.
Results: The results indicated that there was a significant decrease in IL-1ß level in both groups. For the control group, there were significant decreases of the IL-1ß values from the baseline to two weeks and also from the baseline to four weeks, with p-values of 0.0001 for both comparisons. The same results were obtained for the drug group.
Conclusion: It was concluded that it is likely that diacerein may play a therapeutic role as a potent anti-inflammatory drug in the management of periodontitis.
References
Bartold, P.M., Cantley, M.D. and Haynes, D.R. Mechanisms and control of pathologic bone loss in
periodontitis. Periodontol 2000, 2000, 53, 55–69. doi: 10.1111/j.1600-0757.2010.00347.x, PMid: 20403105
Amano, A. Host-parasite interactions in periodontitis: subgingival infection and host sensing. Periodontal
, 2000, 52, 7–11. doi: 10.1111/j.1600-0757.2009.00328.x, PMid: 20017792
Ren-Yeong, H., Sheng-Hua Lu, Kwan-Wei Su, et al. Diacerein: A potential therapeutic drug for
periodontal disease. Medical Hypotheses, 2012, 79, 165–77. doi: 10.1016/j.mehy.2012.04.024, PMid:
Dinarello, C.A. IL-1: discoveries, controversies and future directions. Eur. J. Immunol, 2010, 40, 599–606.
doi: 10.1002/eji.201040319, PMid: 20201008
Graves, D.T. and Cochran, D. The contribution of interleukin-1 and tumor necrosis factor to periodontal
tissue destruction. J. Periodontol, 2003, 74, 391–401. doi: 10.1902/jop.2003.74.3.391, PMid: 12710761
Cochran, D.L. Inflammation and bone loss in periodontal disease. J. Periodontol, 2008, 79, 1569–76. doi:
1902/jop.2008.080233, PMid: 18673012
Gaspersic, R., Stiblar-Martincic, D., Osredkar, J. and Skaleric, U. Influence of subcutaneous administration
of recombinant TNF-alpha on ligature-induced periodontitis in rats. J. Periodontal Res, 2003, 8, 198–203.
doi: 10.1034/j.1600-0765.2003.01395.x
Waykole, Y.P., Doiphode, S.S., Rakhewar, P.S. and Mhaske, M. Anticytokine therapy for periodontal
diseases: where are we now? J. Indian Soc. Periodontol, 2009, 13, 64–8. doi: 10.4103/0972-124X.55837,
PMid: 20407652 PMCid: PMC2847126
Hunter, D.J. and Wise, B. Review diacerein is more effective than placebo and is as effective as NSAIDs
for knee and hip osteoarthritis. Evid Based Med, 2007, 12, 74. doi: 10.1136/ebm.12.3.74, PMid: 17537882
Pujol, J.P., Felisaz, N., Boumediene, K., et al. Effects of diacerein on biosynthesis activities of
chondrocytes in culture. Biorheology, 2000, 37, 177–84. PMid: 10912190
Brandt, K.D. Studies in animal models of osteoarthritis as predictors of a structure-modifying effect of
diacerin in humans with osteoarthritis. Biorheology, 2008, 43,589–594.
Alvarez-Soria, M.A., Herrero-Beaumont, G., Sanchez-Pernaute, O., Bellido, M. and Largo, R. Diacerein
has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast – comparison to its
effects on osteoarthritic chondrocytes. Rheumatology (Oxford), 2008, 47, 627–33. doi:
1093/rheumatology/ken116, PMid: 18375401
Page, R.C. and Schroeder, H.E. Periodontitis in Man and Other Animals. New York: Karger, 1982, 58,106.
Nociti, F.H., Nogueira-Filho, M.T., Primo, M.A., Machado, V., Tramontina, S.P., Barros, A. and Sallum,
E.A. The influence of nicotine on the bone loss rate in ligature-induced periodontitis. A histometric study
in rats. J. Periodontol, 2000, 71, 1460-4. doi: 10.1902/jop.2000.71.9.1460, PMid: 11022776
Nasry, S.A., Zaki, B.M., Elkarargy, A., Aly, A.A. and Omer, M.G. IL-17 Levels in Diabetic and Non- diabetic Experimental Periodontitis: a Pilot Study. Australian Journal of Basic and Applied Sciences, 2011,
, 1466-1474.
Dawson, B. and Trapp, R.G. Basic and Clinical Biostatistics, New York: Lange Medical Books-McGraw
Hill, 2001.
Tamura, T., Kosaka, N., Ishiwa, J., Sato, T., Nagase, H. and Rhein, Ito A. An active metabolite of
diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and upregulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes.
Osteoarthritis Cartilage, 2001, 9, 257–63. doi: 10.1053/joca.2000.0383, PMid: 11300749
Pelletier, J., Yaron, M., Haraoui, B., Cohen, P., Nahir, M.A., Choquette, D., Wigler, I., Rosner, I.A. and
Beaulieu, A.D. Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-
controlled trial. Arthritis & Rheumatism, 2000, 43, 2339–48. doi: 10.1002/1529- 0131(200010)43:10<2339::AID-ANR23>3.0.CO;2-P
Verbruggen, G. Chondro-protective drugs in degenerative joint diseases. Rheumatology (Oxford), 2006,
, 129–38. doi: 10.1093/rheumatology/kei171, PMid: 16278282
Moldovan, F., Pelletier, J.P., Jolicoeur, F.C., Cloutier, J.M. and Martel-Pelletier, J. Diacerein and rhein
reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis
Cartilage, 2000, 8, 186–96. doi: 10.1053/joca.1999.0289, PMid: 10806046
Published
Issue
Section
License
Copyright (c) 2020 knowledge kingdom publishing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
